MGC Pharmaceuticals Ltd. announced the completion of the construction and implementation phase of the CimetrA? production facility in Malta. MGC Pharma received a ?3.1 million cash grant from the Maltese Government via Malta Enterprise, in order to fund the majority of the costs of construction, and equipment fitout of the facility. The fully compliant EU GMP production facility will have the capacity to produce over 20,000 units in liquid dose form per day, which is double that originally planned, (announced in Dec. 2020) making it an important part of MGC's manufacturing pipeline, and to meet CimetrA?'s near term demand. The facility will create a European manufacturing hub for CimetrA? and for other liquid form dose medicines, putting MGC Pharma in a strong position to streamline global distribution through convenient shipping access.